A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

In plain English

What this trial is testing

This study is testing MK-8690 (a drug) as a possible treatment. Condition(s) listed: Colitis Ulcerative and Ulcerative Colitis.

Participants are assigned to groups by chance (randomized).

Some participants receive a placebo or sham for comparison.

It is blinded: participants and the study team do not know who receives what.

Phase 2 studies test whether a treatment shows signs of working, and keep checking safety, in a larger group of people with the condition.

Who can join

• Ages 18 to 75
• Any sex

Some of the main requirements, copied from the record:

• The main inclusion criteria include but are not limited to the following:
• Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before Randomization
• Has moderately to severely active UC
• Has a weight ≥40 kg
• Satisfies at least 1 of the criteria: Has had an inadequate response or loss of response to 1 or more protocol-specified treatments; protocol specified corticosteroid dependence; has been intolerant to 1 or more protocol-specified UC…
• Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable

Plus 14 more requirement(s). Only the trial team can confirm whether you qualify.

What's involved

• About 100 participants are expected to take part.
• The study has 4 groups.
• Start date: 2026-03-24.
• Main results expected around 2027-10-28 (estimate from the record).
• 38 study sites listed (38 marked recruiting) in Canada, Colombia, France, Germany and Greece and 6 more countries.

Groups in this study

• Period 1: MK-8690 (listed as: experimental group)
• Period 1: Placebo (listed as: placebo group)
• Period 2: MK-8690 (listed as: experimental group)
• Period 3: MK-8690 (listed as: experimental group)

Main thing being measured

• Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12 (Week 12)

In the researchers’ words

The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.

This summary was written automatically from the official record using fixed templates (no AI), so it only says what the record says, and may leave things out.